Holen Sie sich die Stockscreener-App
13.73
2.54%
0.34
Handel nachbörslich:
13.48
-0.25
-1.82%
Schlusskurs vom Vortag:
$13.39
Offen:
$13.51
24-Stunden-Volumen:
674.96K
Relative Volume:
0.82
Marktkapitalisierung:
$1.45B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.88M
KGV:
-8.8764
EPS:
-1.5468
Netto-Cashflow:
$-104.72M
1W Leistung:
+1.59%
1M Leistung:
-0.79%
6M Leistung:
-47.23%
1J Leistung:
-19.66%
1-Tages-Spanne:
$13.38
$14.11
1-Wochen-Bereich:
$12.30
$14.11
52-Wochen-Spanne:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
13.73 | 1.41B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise - Bluefield Daily Telegraph
Automated trading signals detected on Edgewise Therapeutics Inc.Weekly Stock Recap & High Accuracy Trade Alerts - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplyOptions Play & Consistent Profit Focused Trading Strategies - Newser
Can trapped investors hope for a rebound in Edgewise Therapeutics Inc.Jobs Report & Daily Momentum Trading Reports - Newser
What high frequency data says about Edgewise Therapeutics Inc.Weekly Trade Report & Weekly Breakout Opportunity Watchlist - Newser
Using AI based signals to follow Edgewise Therapeutics Inc.Quarterly Trade Review & Technical Pattern Based Buy Signals - Newser
Published on: 2025-08-13 06:25:03 - Newser
Using Ichimoku Cloud for Edgewise Therapeutics Inc. technicals2025 Price Targets & High Accuracy Trade Alerts - Newser
How sentiment analysis helps forecast Edgewise Therapeutics Inc. - Newser
Quantitative breakdown of Edgewise Therapeutics Inc. recent moveTrade Exit Report & Fast Exit Strategy with Risk Control - Newser
Is Edgewise Therapeutics Inc. stock entering bullish territoryJuly 2025 Levels & Real-Time Buy Signal Alerts - Newser
Is Edgewise Therapeutics Inc. stock poised for growth [Weekly Risk Summary]Free AI Driven Stock Price Forecasts - Newser
Edgewise Therapeutics Inc. stock trendline breakdown3-Day Market Movement Forecast Analysis - Newser
What candlestick patterns are forming on Edgewise Therapeutics Inc.Portfolio Risk Report & AI Driven Price Forecasts - Newser
How Interest Rate Changes Impact Edgewise Therapeutics Inc. Stock PerformanceWeekly Risk Summary & Safe Capital Growth Stock Tips - Newser
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $49.00 at Royal Bank Of Canada - MarketBeat
Real time scanner hits for Edgewise Therapeutics Inc. explainedDaily Technical Forecast for Quick Gains - Newser
Research Analysts Offer Predictions for EWTX FY2029 Earnings - MarketBeat
Can Edgewise Therapeutics Inc. expand into new marketsAdvanced Entry Signal Stocks - thegnnews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - PR Newswire
What machine learning models say about Edgewise Therapeutics Inc.Trend Confirmation Scanner with Entry Focus - Newser
Applying Wyckoff theory to Edgewise Therapeutics Inc. stockFree Chart Breakout Buy Signal Detection - Newser
Zurcher Kantonalbank Zurich Cantonalbank Has $156,000 Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Is Edgewise Therapeutics Inc. stock poised for growth2-Day Signal Watch with Forecast Outcome - Newser
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $49.00 - Defense World
Edgewise Therapeutics (EWTX) to Release Quarterly Earnings on Thursday - MarketBeat
How Edgewise Therapeutics Inc. stock performs during market volatilityFree Fast Gaining Stock Screener Report - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - GlobeNewswire Inc.
TD Asset Management Inc Makes New $730,000 Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - 富途牛牛
RBC Capital Raises Edgewise PT to $49, Maintains Outperform Rating - AInvest
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.9%Here's Why - MarketBeat
Edgewise Therapeutics Receives Buy Rating from Raymond James with $46 Price Target - AInvest
Edgewise Therapeutics stock price target raised to $49 at RBC Capital - Investing.com Canada
Edgewise Therapeutics shares rise 7.26% premarket after RBC lifts price target to $49. - AInvest
RBC Lifts Price Target on Edgewise Therapeutics to $49 From $48, Keeps Outperform, Speculative Risk - MarketScreener
We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate - uk.finance.yahoo.com
Edgewise Therapeutics Advances in Muscular Dystrophy Trials - TipRanks
Edgewise Therapeutics shares fall 3.40% after-hours following positive trial data announcements. - AInvest
Edgewise Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock with $46 price target - Investing.com Canada
Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating - TipRanks
Edgewise Therapeutics' Accelerating Clinical Pipeline: A Catalyst for Valuation Re-rating in 2025? - AInvest
Edgewise Therapeutics shares surge as Q2 loss narrows, beats estimates By Investing.com - Investing.com South Africa
Edgewise Therapeutics shares surge as Q2 loss narrows, beats estimates - Investing.com India
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):